search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Informatics


companies can boldly reinvent themselves in the same way as Novartis. Fortunately, the majority of organisations may be able to reap the rewards of effective data management and digital transfor- mation without needing to make significant struc- tural changes. Working in close partnerships with specialist technology providers can enable compa- nies to benefit from their technical expertise and apply this knowledge across the research environ- ment. This allows pharmaceutical and biotech- nology companies to fully focus on the output of their drug discovery and development pipeline, directing their resources appropriately and cost effectively to bring better drugs to more patients in less time. With the right support, companies can sharpen and refine their commercial strate- gies to make the best use of the wealth of data that they have at their fingertips, ensuring that they are fit for the challenges of today and the future. Any dynamic and innovative life sciences organi-


sation must now become part of this data revolu- tion. At Aigenpulse, we believe the winners in this total digital transformation will be those who adopt agile approaches, empower scientists and enable data-driven technology throughout their entire research and development process.


DDW


References 1 DiMasi, JA et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33. 2 Burke, M. Why do Alzheimer’s drugs keep failing? Chemistry World. July 2014. Available at: https://www.scientificamerican. com/article/why-alzheimer-s- drugs-keep-failing/. Accessed, June 2018. 3 Nelson, MR et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-60. 4 Chilukuri, S et al. Digital in R&D: The $100 billion opportunity. Available at: https://www.mckinsey.com/ind ustries/pharmaceuticals-and- medical-products/our- insights/digital-in-r-and-d-the- 100-billion-opportunity. Accessed, June 2018. 5 Stephens, ZD et al. Big Data: Astronomical or Genomical? PLoS Biol. 2015 7;13(7):e1002195.


Dr Satnam Surae has been active in the life sci- ences sector for more than 10 years. Satnam received a BSc (Hons) in Biochemistry and MRes in Computational Biology from the University of York (UK), and a PhD in Computational Structural Biology from University College Dublin (Ireland). Subsequently, he worked in industrial biotechnology developing metabolic models, prior to joining Aigenpulse.


Drug Discovery World Summer 2018 73


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80